

17 October 2023

Scancell Holdings plc
("Scancell" or the "Company")

Block Listing Six Monthly Return

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:

Name of applicant:	Scancell Holdings plc			
Number and class of securities originally admitted:	2,880,000 ordinary shares of £0.001 each			
Date of admission:	17 April 2023			
Period of return:	From:	17 April 2023	To:	16 October 2023
Balance of unallotted securities under scheme(s) from previous return:	0			
<u>Plus:</u> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	0			
<u>Less:</u> Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):	1,260,000			
<u>Equals:</u> Balance under scheme(s) not yet issued/allotted at end of period:	1,620,000			
Total number of securities in issue at the end of the period	819,663,561			

For further information, please contact:

Scancell Holdings plc

Dr Jean-Michel Cosséry, Non-Executive Chairman
Professor Lindy Durrant, CEO

+44 (0) 20 3709 5700

Stifel Nicolaus Europe Limited (Nominated Adviser and Join Broker)

Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment Banking)
Nick Adams/Nick Harland (Corporate Broking)

+44 (0) 20 7710 7600

Panmure Gordon (UK) Limited (Joint Broker)

Freddie Crossley/Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)

+44 (0) 20 7886 2500

ICR Consilium

Mary-Jane Elliott/Matthew Neal/Chris Welsh

+44 (0) 20 3709 5700

scancell@consilium-comms.com

17 October 2023

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope[®] and ImmunoBody[®] for vaccines and GlyMab[®] and AvidiMab[®] for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope[®] and ImmunoBody[®]) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab[®]) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab[®]).

For further information about Scancell, please visit: <https://www.scancell.co.uk/>